Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase – Should You Buy?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) saw strong trading volume on Wednesday . 636,943 shares were traded during trading, an increase of 130% from the previous session’s volume of 277,509 shares.The stock last traded at $19.57 and had previously closed at $18.88.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 21st. BTIG Research started coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Buy” and a consensus price target of $38.75.

Enliven Therapeutics Price Performance

The firm’s 50 day moving average is $21.18 and its 200 day moving average is $23.70. The company has a market capitalization of $973.22 million, a PE ratio of -10.45 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the completion of the transaction, the chief financial officer now owns 23,000 shares in the company, valued at approximately $490,590. This represents a 12.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the sale, the chief executive officer now owns 990,392 shares in the company, valued at approximately $20,629,865.36. This trade represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 72,784 shares of company stock valued at $1,607,736. 29.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its position in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after purchasing an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Enliven Therapeutics during the fourth quarter valued at $97,000. BNP Paribas Financial Markets bought a new stake in Enliven Therapeutics in the fourth quarter worth $112,000. ExodusPoint Capital Management LP purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth $200,000. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth $228,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.